CO2022017112A2 - N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30 - Google Patents
N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30Info
- Publication number
- CO2022017112A2 CO2022017112A2 CONC2022/0017112A CO2022017112A CO2022017112A2 CO 2022017112 A2 CO2022017112 A2 CO 2022017112A2 CO 2022017112 A CO2022017112 A CO 2022017112A CO 2022017112 A2 CO2022017112 A2 CO 2022017112A2
- Authority
- CO
- Colombia
- Prior art keywords
- cyanopyrrolidines
- activity
- ubiquitin
- specific peptidase
- peptidase inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008401.8A GB202008401D0 (en) | 2020-06-04 | 2020-06-04 | Novel compounds |
| GBGB2016689.8A GB202016689D0 (en) | 2020-10-21 | 2020-10-21 | Novel compounds |
| GBGB2101935.1A GB202101935D0 (en) | 2021-02-11 | 2021-02-11 | Novel compounds |
| PCT/EP2021/064897 WO2021245186A1 (en) | 2020-06-04 | 2021-06-03 | N-cyanopyrrolidines with activity as usp30 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022017112A2 true CO2022017112A2 (es) | 2022-12-09 |
Family
ID=76421953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0017112A CO2022017112A2 (es) | 2020-06-04 | 2022-11-29 | N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230303547A1 (https=) |
| EP (1) | EP4161920A1 (https=) |
| JP (1) | JP7796047B2 (https=) |
| KR (1) | KR20230019198A (https=) |
| CN (1) | CN115698001A (https=) |
| AU (1) | AU2021285130A1 (https=) |
| BR (1) | BR112022019722A2 (https=) |
| CA (1) | CA3185654A1 (https=) |
| CO (1) | CO2022017112A2 (https=) |
| IL (1) | IL298710A (https=) |
| MX (1) | MX2022015254A (https=) |
| WO (1) | WO2021245186A1 (https=) |
| ZA (1) | ZA202213866B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024544660A (ja) | 2021-12-01 | 2024-12-03 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| CN119528901A (zh) * | 2024-11-05 | 2025-02-28 | 上海市同济医院 | 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| EP1272467A4 (en) | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine protease inhibitors |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| SG174050A1 (en) | 2006-04-13 | 2011-09-29 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| TWI433677B (zh) | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129371A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129365A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| RS58361B1 (sr) | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CA2976741C (en) * | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| US11014912B2 (en) | 2016-09-27 | 2021-05-25 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) * | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
-
2021
- 2021-06-03 US US18/007,641 patent/US20230303547A1/en active Pending
- 2021-06-03 EP EP21731947.4A patent/EP4161920A1/en active Pending
- 2021-06-03 IL IL298710A patent/IL298710A/en unknown
- 2021-06-03 CN CN202180038498.9A patent/CN115698001A/zh active Pending
- 2021-06-03 CA CA3185654A patent/CA3185654A1/en active Pending
- 2021-06-03 MX MX2022015254A patent/MX2022015254A/es unknown
- 2021-06-03 WO PCT/EP2021/064897 patent/WO2021245186A1/en not_active Ceased
- 2021-06-03 KR KR1020237000160A patent/KR20230019198A/ko active Pending
- 2021-06-03 BR BR112022019722A patent/BR112022019722A2/pt unknown
- 2021-06-03 AU AU2021285130A patent/AU2021285130A1/en active Pending
- 2021-06-03 JP JP2022571212A patent/JP7796047B2/ja active Active
-
2022
- 2022-11-29 CO CONC2022/0017112A patent/CO2022017112A2/es unknown
- 2022-12-21 ZA ZA2022/13866A patent/ZA202213866B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7796047B2 (ja) | 2026-01-08 |
| US20230303547A1 (en) | 2023-09-28 |
| JP2023529570A (ja) | 2023-07-11 |
| KR20230019198A (ko) | 2023-02-07 |
| EP4161920A1 (en) | 2023-04-12 |
| CA3185654A1 (en) | 2021-12-09 |
| MX2022015254A (es) | 2023-01-11 |
| IL298710A (en) | 2023-02-01 |
| WO2021245186A1 (en) | 2021-12-09 |
| ZA202213866B (en) | 2024-07-31 |
| BR112022019722A2 (pt) | 2022-12-20 |
| AU2021285130A1 (en) | 2023-01-19 |
| CN115698001A (zh) | 2023-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022003608A2 (es) | Cianopirrolidinas sustituidas con actividad como inhibidores de usp30 | |
| CO2022017112A2 (es) | N-cianopirrolidinas con actividad como inhibidores de peptidasa específica de ubiquitina 30 | |
| CO2022014134A2 (es) | N-cianopirrolidinas con actividad como inhibidores de usp30 | |
| MX387482B (es) | Derivados de n-cianopirrolidina de fórmula (i) con actividad como inhibidores de la peptidasa específica de ubiquitina (usp30). | |
| MX2018005925A (es) | Purinonas como inhibidores de proteasa específica de ubiquitina 1. | |
| CO2022017233A2 (es) | 1-(5-(2-cianopiridin-4-il)oxazol-2-carbonil)-4-metilhexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilo como inhibidor de usp30 para uso en el tratamiento de la disfunción mitocondrial, cáncer y fibrosis | |
| ECSP034568A (es) | Inhibidores de metaloproteinasa del tipo pirimidin 2,4,6-triona | |
| PH12023550161A1 (en) | Pharmaceutical composition and use thereof | |
| MX2023000731A (es) | Composiciones utiles para enzimas de internalizacion. | |
| EA201592215A1 (ru) | Антисмысловые олигомеры и их конъюгаты, направленные на пропротеин конвертазу субтилизин/кексин типа 9 (pcsk9) | |
| GT200300245A (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
| AR030741A1 (es) | Derivados de los acidos 2-amino-2-alquil-5-heptenoico y - heptinoico utiles como inhibidores de oxido nitrico sintetasa | |
| GT200600097A (es) | Formas farmaceuticas con propiedades farmacocineticas mejoradas | |
| MX2024006368A (es) | Composiciones moduladoras de complemento del factor b y metodos de uso de estas. | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| ATE541581T1 (de) | Medikament für die krebstherapie | |
| MX2021001361A (es) | Composicion liquida de fibrinogeno humano. | |
| AR099811A1 (es) | Microorganismos con una productividad de aminoácidos l mejorada y proceso para producir aminoácidos l | |
| MX2024004034A (es) | Composiciones de arilsulfatasa y usos farmaceuticos de las mismas en el sistema nervioso central (cns). | |
| CL2021000404A1 (es) | Cepa rhodococcus rhodochrous y uso de la misma en la producción de ácido acrílico | |
| CR8439A (es) | Metodo para mejorar la eficacia de drogas terapeuticas radio rotuladas | |
| UY5093S (es) | Modelo industrial de automóvil | |
| MX2018010435A (es) | Composiciones farmaceuticas disuasivas del abuso. | |
| MX2024006560A (es) | Proteasas fungicas, composiciones tratadas y usos de estas. | |
| CL2024002553A1 (es) | Compuesto de indazol y su uso farmacéutico. |